Abstract
0139 SUVN-G3031, A Potent and Selective Histamine H3 Receptor Inverse Agonist - Phase-2 Investigational New Drug for the Treatment of Narcolepsy - Differentiating Factors with Competitor Clinical Candidates
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have